Loading clinical trials...
Loading clinical trials...
A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Conditions
Interventions
Chimeric Antigen Receptor Modified T cells Targeting CD19
Locations
1
China
Southwest Hospital of Third Millitary Medical University
Chongqing, Chongqing Municipality, China
Start Date
December 1, 2014
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2023
Last Updated
June 25, 2019
NCT07388563
NCT05529069
NCT06263491
NCT06285890
NCT05139017
NCT00106925
Lead Sponsor
Southwest Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions